Literature DB >> 25031802

Efficacy of inhaled iloprost in cor pulmonale and severe pulmonary hypertension associated with tuberculous destroyed lung.

Yae Min Park1, Wook-Jin Chung1, Sang Pyo Lee2, Deok Young Choi3, Han Joo Baek4, Sung Hwan Jung2, In Suck Choi1, Eak Kyun Shin1.   

Abstract

Chronic obstructive pulmonary disease (COPD) is one of the causes of cor pulmonale. Cor pulmonale patients with pulmonary hypertension have a significant lower survival rate than patients without. However, there is no conclusive treatment options in cor pulmonale and pulmonary hypertension associated with COPD until now. We report a patient with cor pulmonale and pulmonary hypertension associated with severe form of COPD and tuberculous destroyed lung who achieved marked clinical, functional and echocardiographic hemodynamic improvements with inhaled iloprost for six months.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Cor pulmonale; Iloprost; Pulmonary hypertension; Tuberculous destroyed lung

Year:  2014        PMID: 25031802      PMCID: PMC4096673          DOI: 10.4250/jcu.2014.22.2.95

Source DB:  PubMed          Journal:  J Cardiovasc Ultrasound        ISSN: 1975-4612


  9 in total

1.  Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension.

Authors:  Christian F Opitz; Roland Wensel; Jörg Winkler; Michael Halank; Leonhard Bruch; Franz-Xaver Kleber; Gert Höffken; Stefan D Anker; Abdissa Negassa; Stephan B Felix; Roland Hetzer; Ralf Ewert
Journal:  Eur Heart J       Date:  2005-05-11       Impact factor: 29.983

2.  Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation.

Authors:  C F Opitz; R Wensel; M Bettmann; R Schaffarczyk; M Linscheid; R Hetzer; R Ewert
Journal:  Eur Heart J       Date:  2003-02       Impact factor: 29.983

3.  Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue.

Authors:  M M Hoeper; M Schwarze; S Ehlerding; A Adler-Schuermeyer; E Spiekerkoetter; J Niedermeyer; M Hamm; H Fabel
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

4.  Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure.

Authors:  M Oswald-Mammosser; E Weitzenblum; E Quoix; G Moser; A Chaouat; C Charpentier; R Kessler
Journal:  Chest       Date:  1995-05       Impact factor: 9.410

5.  Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease.

Authors:  Tarek A Dernaika; Mikel Beavin; Gary T Kinasewitz
Journal:  Respiration       Date:  2009-09-25       Impact factor: 3.580

Review 6.  Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Drugs       Date:  2009-06-18       Impact factor: 9.546

7.  Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension.

Authors:  Matthew J Hegewald; C Gregory Elliott
Journal:  Chest       Date:  2009-02       Impact factor: 9.410

8.  Influence of inhaled iloprost on transpulmonary gradient of big endothelin in patients with pulmonary hypertension.

Authors:  H Wilkens; M Bauer; N Forestier; J König; A Eichler; S Schneider; H J Schäfers; G W Sybrecht
Journal:  Circulation       Date:  2003-03-25       Impact factor: 29.690

9.  Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial.

Authors:  Lucas Boeck; Michael Tamm; Peter Grendelmeier; Daiana Stolz
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

  9 in total
  1 in total

1.  PTBP1 Targets ILK to Regulate the Hypoxia-Induced Phenotypic Transformation of Pulmonary Artery Smooth Muscle Cells.

Authors:  Gaoliang Yan; Renhua Sun; Zhongpu Chen; Xiaodong Pan; Zulong Sheng; Chengchun Tang
Journal:  Drug Des Devel Ther       Date:  2021-05-13       Impact factor: 4.162

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.